Physician profile
Dane J Dickson
NPI 1669497194
$21,154.64
in general payments reported to CMS, 2019-2025
67 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,235 · 2020: $1,437 · 2021: $1,297 · 2022: $1,408 · 2023: $10K · 2024: $1,094 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,260 · Food and Beverage: $3,951 · Travel and Lodging: $1,282 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,260.00 |
| Food and Beverage | $3,950.58 |
| Travel and Lodging | $1,281.85 |
| Education | $284.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $8,671.13 | 2023 | Cologuard Collection Kit |
| Advanced Accelerator Applications | $3,000.00 | 2019 | |
| Pfizer INC. | $819.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $751.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $699.73 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $645.67 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $565.39 | 2019-2025 | Rybrevant, Erleada, Balversa |
| Astellas Pharma US INC | $548.77 | 2019-2023 | Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $460.42 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $440.93 | 2020-2025 | |
| Daiichi Sankyo INC. | $435.49 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Amgen INC. | $371.88 | 2019-2023 | Lumakras, Nplate, Xgeva |
| Eisai INC. | $304.00 | 2019-2024 | |
| Genentech USA, INC. | $274.57 | 2019-2025 | Alecensa, Tecentriq, Rozlytrek |
| Celgene Corporation | $219.27 | 2019-2025 | Reblozyl, Pomalyst |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.